Vor Bio appoints Navid Khan as chief medical affairs officer

CAMBRIDGE, Mass. - Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company focused on autoimmune diseases with a market capitalization of $191 million, announced Tuesday the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 3.49, indicating robust short-term financial health.

Dr. Khan brings over 20 years of experience across medical affairs, commercial, and R&D functions. He previously served as Head of Neuromuscular Therapeutic Area, Medical Affairs at argenx, where he led medical strategy for VYVGART and VYVGART Hytrulo launches for generalized myasthenia gravis.

"Navid is an exceptional leader with a proven track record of building world-class medical affairs organizations and executing multiple high-impact product launches," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board of Vor Bio, according to the company’s press release.

Prior to argenx, Khan held senior leadership positions at Akouos Inc. and Sarepta Therapeutics, where he contributed to the launch of three Duchenne muscular dystrophy therapies. He also worked at EMD Millipore for over a decade in various roles spanning R&D, viral vector and vaccine strategy, and commercial leadership.

Khan has overseen more than 40 development programs in neurology, immunology, and infectious diseases throughout his career. He holds a Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts, Lowell, and a B.S. in Biochemistry and Molecular Biology from the University of Massachusetts, Amherst.

Vor Bio is currently advancing telitacicept, a dual-target fusion protein, through Phase 3 clinical development for autoantibody-driven conditions. While the company’s stock has shown significant volatility, InvestingPro analysis reveals 15+ additional investment insights available to subscribers, including detailed financial health metrics and growth projections.

In other recent news, Vor Biopharma Inc. reported significant developments in its clinical and corporate activities. The company announced the presentation of 48-week clinical data from a Phase 3 study of telitacicept for generalized myasthenia gravis, conducted in collaboration with RemeGen Co., Ltd. Vor Biopharma also revealed that its collaborator achieved the primary endpoint in a Phase 3 study for telitacicept in IgA nephropathy, showing a notable reduction in urine protein-to-creatinine ratio. On the corporate front, Vor Biopharma implemented a 1-for-20 reverse stock split, approved by shareholders at a special meeting. Additionally, the company experienced several changes in its board of directors, with three resignations and a new appointment. Shareholders also approved amendments to the company’s 2021 Equity Incentive Plan, increasing the share reserve and adjusting the annual automatic increase. These developments reflect ongoing strategic and operational adjustments within the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.